Translating Pharmacogenomics: Challenges on the Road to the Clinic
Open Access
- 14 August 2007
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 4 (8) , e209
- https://doi.org/10.1371/journal.pmed.0040209
Abstract
Pharmacogenomics is one of the first clinical applications of the postgenomic era. It promises personalized medicine rather than the established “one size fits all” approach to drugs and dosages. The expected reduction in trial and error should ultimately lead to more efficient and safer drug therapy. In recent years, commercially available pharmacogenomic tests have been approved by the Food and Drug Administration (FDA), but their application in patient care remains very limited. More generally, the implementation of pharmacogenomics in routine clinical practice presents significant challenges. This article presents specific clinical examples of such challenges and discusses how obstacles to implementation of pharmacogenomic testing can be addressed.Keywords
This publication has 70 references indexed in Scilit:
- Adding pharmacogenetics information to drug labels: lessons learnedPharmacogenetics and Genomics, 2006
- The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population GeneticsJournal of Clinical Oncology, 2006
- Pharmacogenetics, Adverse Drug Reactions and Public HealthPublic Health Genomics, 2006
- Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?Nature Reviews Drug Discovery, 2005
- Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?Pharmacogenetics and Genomics, 2005
- Pharmacogenomics: bench to bedsideNature Reviews Drug Discovery, 2004
- Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjectsEuropean Journal of Clinical Pharmacology, 2003
- Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 GenotypesJournal of Clinical Oncology, 2002
- Implications of the Human Genome Project for Medical ScienceJAMA, 2001